EAGLE PHARMACEUTICALS, INC. Quarterly Deferred Income Tax Liabilities, Net in USD from Q4 2021 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Summary
Eagle Pharmaceuticals, Inc. quarterly Deferred Income Tax Liabilities, Net history and growth rate from Q4 2021 to Q3 2022.
  • Eagle Pharmaceuticals, Inc. Deferred Income Tax Liabilities, Net for the quarter ending September 30, 2022 was $4.54M.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q3 2022 $4.54M Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $4.54M Jun 30, 2022 10-Q 2022-08-09
Q4 2021 $0 Dec 31, 2021 10-Q 2022-11-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.